Project Grant R01EB039040
- Federal Project Grant Award Summary The Leland Stanford Junior University received a $1.41 million Project Grant from the National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), awarded September 1, 2025, through August 31, 2028. This award funds research to develop synthetic cell state engineering technologies for primary human cellular therapies, with applications to cancer immunotherapy. The project delivers two primary technical...
- Federal Grant Award Summary The Leland Stanford Junior University received a $1.4 million Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective August 15, 2025, with a completion date of July 31, 2028. The award supports research in combinatorial engineering of multicellular synthetic immunotherapy systems, focusing on the development of advanced cell therapy technologies to enhance cancer...
- Federal Grant Award Summary The Leland Stanford Junior University received a $616,000 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on March 12, 2026, with a completion date of February 29, 2028. The award supports the development of next-generation proximity labeling (PL) enzymes to advance spatial proteomics research in living cells. The project focuses on engineering and...
- Federal Grant Award Summary Stanford University received a $427,079 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025, through July 31, 2027. The award supports the development of DNA transistors for cellular programming—innovative molecular tools designed to provide precise, modular, and multiplexed control over cellular functions. Leveraging DNA-binding...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded The Leland Stanford Junior University a Project Grant of $428,089 under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) for the period April 1, 2026 through March 31, 2028. The grant funds development of a recombinant engineered, conductive, injectable, and biodegradable hydrogel incorporating electrically-conductive protein...
- Federal Project Grant Award Summary The Leland Stanford Junior University received a $157,388 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), awarded on August 9, 2026, with a completion date of August 8, 2027. The research project, titled "Rewiring Nucleosome Engagement Through Chemically Induced Proximity," investigates the application of chemically induced proximity (CIP)...
- Federal Grant Award Summary The National Institute of General Medical Sciences (NIGMS) awarded Stanford University a $462,119 Project Grant on September 8, 2025, under the Biomedical Research and Research Training program (CFDA 93.859) to develop and deploy TRACK-IT (Transposon Accelerated Chromatin Kinetic Imaging Technology), a next-generation live-imaging platform for studying three-dimensional genome motion and dynamics. The research aims to advance understanding of how genome organization...
- Federal Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded The Leland Stanford Junior University a $1.24 million Project Grant under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop a hydrogel-based delivery platform for bacteriophage therapy targeting antibiotic-resistant wound infections. The research, conducted in Palo Alto, California, focuses on engineering dynamic...
- Federal Project Grant Award Summary The Leland Stanford Junior University received a $300,000 Project Grant from the National Science Foundation's Division of Chemical, Bioengineering, Environmental, and Transport Systems under the Engineering program (CFDA 47.041), effective September 1, 2025, through August 31, 2027. This award supports the "BRING-SYNBIO: Proteolytic Dosage Control of Protein Circuits to Modulate Intercellular Communications" project, conducted in Palo Alto,...
- Federal Grant Award Summary The Leland Stanford Junior University received a $384,999 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective August 12, 2025, with a completion date of July 31, 2030. The award funds research to develop precision disease-responsive gene therapies that enable dynamic control of gene expression in real-time. The project centers on two primary research objectives:...
Federal Project Grant Award Summary The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded The Leland Stanford Junior University a $460,349 Project Grant effective May 8, 2026, through February 28, 2030, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award supports development of a cell-based macromolecule delivery platform termed "TROGOCYTOSIS-based Transfer and Functional Effector Release" (TRANSFER), which leverages engineered cell-to-cell contact to deliver therapeutic cargos such as CRISPR-Cas9 and base editors to target cells. The research aims to overcome existing delivery limitations associated with viral vectors and nanoparticles by utilizing autologous or allogeneic cells as vehicles, enabling precise, context-dependent delivery through a pH-sensitive fusogen mechanism that facilitates cargo release within recipient cell cytosol or nucleus. Research deliverables under this award include optimization of TRANSFER using primary donor cells (T cells and retinal pigment epithelial cells) with refined transmembrane domains, fusogens, and release domains; development of targeting strategies for primary recipient cells; and expansion of cargo delivery capabilities. Upon completion, the research is expected to demonstrate therapeutic applications for disease treatment in vivo and advance the translational potential of cell-based therapeutic delivery systems. Performance of the research will occur at Stanford University's Palo Alto, California facility.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $460.3k | 5/11/26 |